Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 4/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.50 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4552782 | 0.94 | ROCK2 (0.51) | ROCK2ROCK1TDP1MMP13 | |
| SCHEMBL4882767 | 0.92 | ROCK2 (0.56) | ROCK2ROCK1TDP1MMP13 | |
| SCHEMBL14425153 | 0.91 | SMYD3 (0.49) | ROCK2ROCK1 | |
| SCHEMBL13373545 | 0.90 | EGLN1 (0.47) | ROCK2ROCK1 | |
| SCHEMBL5525010 | 0.84 | ACACB (0.48) | ROCK2ROCK1NPC1L1 | |
| SCHEMBL5525008 | 0.84 | ACACB (0.48) | ROCK2ROCK1NPC1L1 | |
| SCHEMBL5522741 | 0.83 | NPC1L1 (0.54) | ROCK2ROCK1NPC1L1 | |
| SCHEMBL5521879 | 0.83 | ROCK2 (0.50) | ROCK2ROCK1NPC1L1 | |
| SCHEMBL5522737 | 0.83 | NPC1L1 (0.54) | ROCK2ROCK1NPC1L1 | |
| SCHEMBL5521874 | 0.83 | ROCK2 (0.50) | ROCK2ROCK1NPC1L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010526-A1 | BENZIMIDAZOLE 5-SULFONAMIDE DERIVATIVES AS CANNABINOID 1 (CB1) RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | claimed |
| WO-2007120101-A1 | BENZIMIDAZOLE 5-SULFONAMIDE DERIVATIVES AS CANNABINOID 1 (CB1) RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | claimed |
| CN-110382492-B | Microbiocidal oxadiazole derivatives | 先正达参股股份有限公司 | 2023-07-14 | — | — | CN | disclosed |
| US-20220194907-A1 | PROCESS FOR THE PREPARATION OF MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2022-06-23 | — | — | US | disclosed |
| US-11358957-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2022-06-14 | — | — | US | disclosed |
| WO-2021032148-A1 | AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2021-02-25 | — | — | WO | disclosed |
| US-20200277287-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2020-09-03 | — | — | US | disclosed |
| EP-3400223-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | Syngenta Participations AG (CH) | 2018-11-14 | — | — | EP | disclosed |
| WO-2018158365-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2018-09-07 | — | — | WO | disclosed |
| WO-2017118689-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277287-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | PRF1, NOX1, ARG2 | ROCK2 3546/4885ROCK1 2132/4885NPC1L1 712/4885 |
| US-11358957-B2 | Microbiocidal oxadiazole derivatives | PRF1, NOX1, ARG2 | ROCK2 3546/4885ROCK1 2132/4885NPC1L1 712/4885 |
| US-20220194907-A1 | PROCESS FOR THE PREPARATION OF MICROBIOCIDAL OXADIAZOLE DERIVATIVES | CYP51A1, MPO, NOX5 | ROCK2 4330/4885ROCK1 3450/4885NPC1L1 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.